Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes and ATR kinase inhibitor VX-970 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.